3218.TWO Universal Vision Biotechnology Co Ltd
- Market cap
- TWD 10.7B
- P/E
- 9.4x
- P/B
- 2.71x
- ROE
- 26.2%
- Dividend yield
- 5.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3218.TWO undervalued?
Graham number3218.TWO trades 6.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Universal Vision Biotechnology Co Ltd fundamental analysis
No fundamental analysis for Universal Vision Biotechnology Co Ltd yet.
Universal Vision Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd., a biotech company, provides vision care services in Taiwan and China. The company offers various glasses and lenses for vision correction, contact lens solutions, and related eye care products; equipment rental and technical services for laser vision correction instruments; and technology and services for cataract and dry eye examination and treatment instruments. It also trades in medical and pharmaceutical consumables, including op…
Full company profileUniversal Vision Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Universal Vision Biotechnology Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.07B | 1.08B | 1.19B | 1.42B | 2.05B | 2.63B | 3.49B | 4.08B | 4.23B | 4.20B | 4.43B |
| Gross Profit | 591M | 587M | 648M | 817M | 1.27B | 1.64B | 2.14B | 2.45B | 2.53B | 2.48B | 2.55B |
| Operating Income | 114M | 129M | 140M | 247M | 613M | 777M | 1.11B | 1.34B | 1.40B | 1.38B | 1.36B |
| EBITDA | - | 246M | 296M | 373M | 877M | 1.10B | 1.49B | 1.78B | 1.86B | 1.91B | 1.91B |
| Net Income | 91.8M | 120M | 161M | 238M | 483M | 595M | 851M | 1.05B | 1.06B | 1.04B | 1.01B |
| EPS | - | 1.58 | 2.12 | 2.80 | 5.69 | 7.02 | 10 | 12 | 13 | 12 | 12 |
| Balance Sheet | |||||||||||
| Total Assets | 1.74B | 2.00B | 2.10B | 2.65B | 3.17B | 3.75B | 4.51B | 5.13B | 5.76B | 6.09B | 6.40B |
| Total Liabilities | 583M | 422M | 488M | 952M | 1.13B | 1.42B | 1.68B | 1.79B | 2.01B | 1.93B | 2.50B |
| Shareholders' Equity | 1.16B | 1.41B | 1.48B | 1.59B | 1.91B | 2.19B | 2.66B | 3.18B | 3.62B | 4.02B | 3.87B |
| Cash & Short-term Investments | 256M | 614M | 466M | 711M | 1.08B | 1.04B | 1.28B | 1.64B | 507M | 779M | 1.00B |
| Total Debt | - | - | - | 473M | 614M | 768M | 784M | 778M | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 255M | 236M | 273M | 419M | 827M | 912M | 1.27B | 1.55B | 1.67B | 1.67B | 1.87B |
| Capital Expenditure | 174M | 135M | 205M | 235M | 299M | 329M | 493M | 474M | 437M | 564M | 298M |
| Free Cash Flow | - | 101M | 66.7M | 184M | 529M | 583M | 775M | 1.08B | 1.23B | 1.10B | 1.58B |
| Ratios | |||||||||||
| ROE | 7.9% | 8.5% | 10.9% | 15.0% | 25.2% | 27.2% | 31.9% | 32.9% | 29.4% | 25.9% | 26.2% |
| ROA | 5.3% | 6.0% | 7.7% | 9.0% | 15.2% | 15.9% | 18.9% | 20.4% | 18.5% | 17.1% | 15.9% |
| Net Profit Margin | 8.6% | 11.1% | 13.5% | 16.8% | 23.5% | 22.6% | 24.3% | 25.6% | 25.2% | 24.8% | 22.9% |
| Debt to Equity | - | - | - | 0.30x | 0.32x | 0.35x | 0.29x | 0.24x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Universal Vision Biotechnology Co Ltd dividends
- Dividend yield
- 5.93%
- Forward dividend
- 7.75 TWD
- Payout ratio
- 60.9%
- Ex-dividend date
- Mar 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 635M | 7.50 | 60.9% |
| 2024 | TWD 593M | 7.00 | 55.7% |
| 2023 | TWD 480M | 5.65 | 45.9% |
| 2022 | TWD 381M | 4.49 | 44.8% |
| 2021 | TWD 320M | 3.77 | 53.7% |
| 2020 | TWD 152M | 1.79 | 31.5% |
| 2019 | TWD 95.2M | 1.12 | 40.0% |
| 2018 | TWD 91.3M | 1.20 | 56.6% |
| 2017 | TWD 87.5M | 1.15 | 72.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1060:1000 on Aug 25, 2023.
Who owns Universal Vision Biotechnology Co Ltd
- Insiders 52.37%
- Institutions 3.40%
- Public & others 44.24%
- Shares outstanding 84.7M
- Free float 43.2M
Universal Vision Biotechnology Co Ltd company profile
- Company name
- Universal Vision Biotechnology Co Ltd
- Ticker
- 3218.TWO
- ISIN
- TW0003218004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- Building G, Taipei, Taiwan, 115
- Phone
- 886 2 2655 8000
- Website
- uvb.com.tw
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd., a biotech company, provides vision care services in Taiwan and China. The company offers various glasses and lenses for vision correction, contact lens solutions, and related eye care products; equipment rental and technical services for laser vision correction instruments; and technology and services for cataract and dry eye examination and treatment instruments. It also trades in medical and pharmaceutical consumables, including ophthalmic drugs, medical supplies, and consumables; and provides administrative and other professional logistics support services for cooperative clinics and eye centers, as well as brand licensing and consulting services. The company offers its products through its self-operated eyeglasses stores. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan.
Universal Vision Biotechnology Co Ltd management
6- Mr. Zhenghong LuGM & Manager
- Mr. Pi-Jung LinFounder, President, CTO & Representative Director
- Yujiao SunDirector of Finance & Accounting and Accounting Supervisor
- Mr. Yu-chi ChanDirector of Human Resources & Administration Division
- Mr. Chien-Hsiang YuDirector of Marketing Division
- Ms. Shu-Hsin LinChief Auditor of Audit Office